Processa Pharmaceuticals to Host Conference Call to Discuss Third Quarter 2022 Results and Provide Drug Development Update on November 8, 2022 at 4:30 p.m. EST
Processa Pharmaceuticals (Nasdaq: PCSA) will hold a conference call on November 8, 2022, at 4:30 p.m. EST to discuss its Q3 2022 results and provide updates on its clinical pipeline. Interested participants can join via toll-free number 888-506-0062 or through an online webcast. The company focuses on developing treatments for patients with unmet medical needs, with ongoing clinical programs including PCS6422 for cancer and PCS499 for ulcerative necrobiosis lipoidica.
- None.
- None.
HANOVER, MD, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA), a clinical stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have an unmet medical need condition announces today it will host a conference call and live webcast on November 8, 2022, at 4:30 p.m. EST to discuss its third quarter 2022 results and provide an update on its clinical pipeline.
Conference Call Information
To participate in this event, please log-on or dial-in approximately 5 to 10 minutes before the beginning of the call.
Date: November 8, 2022
Time: 4:30 p.m. EST
Toll Free: 888-506-0062
International: 973-528-0011
Entry Code: 178912
Live Webcast: https://www.webcaster4.com/Webcast/Page/2572/46906
Conference Call Replay Information
Toll-free: 877-481-4010
International: 919-882-2331
Replay Passcode: 46906
Replay Webcast: https://www.webcaster4.com/Webcast/Page/2572/46906
About Processa Pharmaceuticals, Inc.
The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life. The Company uses these criteria for selection to further develop its pipeline programs to achieve high-value milestones effectively and efficiently. Active clinical pipeline programs include: PCS6422 (metastatic colorectal, breast cancer), PCS499 (ulcerative necrobiosis lipoidica) and PCS12852 (gastroparesis, functional constipation). The members of the Processa development team have been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and more than 100 FDA meetings throughout their careers. For more information, visit the company’s website at www.processapharma.com.
Forward-Looking Statements
This release contains forward-looking statements. The statements in this press release that are not purely historical are forward-looking statements which involve risks and uncertainties. Actual future performance outcomes and results may differ materially from those expressed in forward-looking statements. Please refer to the documents filed by Processa Pharmaceuticals with the SEC, specifically the most recent reports on Forms 10-K and 10-Q, which identify important risk factors which could cause actual results to differ from those contained in the forward-looking statements.
For More Information:
Michael Floyd
mfloyd@processapharma.com
301-651-4256
Patrick Lin
925-683-3218
plin@processapharma.com
FAQ
When is the Processa Pharmaceuticals conference call scheduled?
What is the purpose of the conference call by Processa Pharmaceuticals?
How can I access the Processa Pharmaceuticals conference call?
What are the ongoing clinical programs at Processa Pharmaceuticals?
What is the ticker symbol for Processa Pharmaceuticals?
